Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Evidence suggests that Journavx doesn't pose a risk of addiction as opioid medications do, making it a potentially safer alternative for pain management. "A new therapeutic class of non-opioid ...

Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

“With the approval of Journavx, a non-opioid ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive ...

Journavx was evaluated in two random double ... "We have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Kewalramani said.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine ... is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, acting director ...

[Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies,” he said. Learn more about Journavx in the YouTube clip below.